Moberg Pharma AB (Formerly known as Moberg Derma) and Menarini Asia-Pacific Group (Formerly Invida Group) Extend Distribution Agreement for Kerasal Nail to China

Published: Jul 23, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

SINGAPORE--(BUSINESS WIRE)--Moberg Pharma AB (OMX: MOB) today announced that Menarini Asia-Pacific, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Kerasal Nail™ in China. The companies now intend to seek marketing authorization for the product in the Chinese market. Kerasal Nail™ (Nalox® or Emtrix® in certain markets) is a non-prescription product for the treatment of discoloured and deformed nails resulting from fungal infection or psoriasis, with a unique mechanism of action that generates visible improvements within 2-4 weeks of treatment. The product became the market leader in the Nordic region immediately after launch in 2011 and has been launched in more than 25 countries, including the U.S. where it has a leading position.

Help employers find you! Check out all the jobs and post your resume.

Back to news